论文部分内容阅读
目的:研究糖尿病围手术期应用胰岛素泵持续皮下输注胰岛素的临床疗效。方法:68例糖尿病围手术期患者随机分为33例采用胰岛素泵持续皮下输注胰岛素治疗(CSII组),对照组35例采用常规多次皮下注射胰岛素治疗(MSII组),分别对术前、术后的相关指标进行对比研究。结果:治疗后两组各时点血糖均较治疗前显著下降(P<0.01)。CSII组达到目标血糖所用的时间明显少于MSII组(2.9比7.2天)(P<0.05),血糖达标率优于MSII组(93.9%比77.1%)(P<0.05),低血糖发生率低于MSII组(9.1%比34.3%)(P<0.01)。待手术时间(4.2比9.4天)和住院时间(16比24天)明显缩短(P<0.05),但两组住院总费用无差异(P>0.05)。结论:CSII在糖尿病患者围手术期中应用疗效及安全性方面优于MSII。
Objective: To study the clinical efficacy of continuous subcutaneous infusion of insulin with insulin pump during perioperative period of diabetes mellitus. Methods: Sixty-eight patients undergoing perioperative diabetes mellitus were randomly divided into three groups: insulin-administered continuous insulin pump (CSII group) and insulin control group (35 cases). The control group received conventional subcutaneous insulin injections (MSII group) Postoperative related indicators for comparative study. Results: After treatment, the levels of blood glucose in each group were significantly lower than those before treatment (P <0.01). The time taken by CSII group to achieve the target blood glucose was significantly less than that of the MSII group (2.9 vs. 7.2 days) (P <0.05), and the blood glucose compliance rate was superior to the MSII group (93.9% vs. 77.1%, P <0.05) In the MSII group (9.1% vs. 34.3%) (P <0.01). The operative time (4.2 vs. 9.4 days) and hospital stay (16 to 24 days) were significantly shorter (P <0.05), but there was no difference in total hospitalization costs between the two groups (P> 0.05). Conclusion: CSII is superior to MSII in the efficacy and safety of perioperative treatment of diabetic patients.